These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 16529599)

  • 1. The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement.
    Campbell J; Seymour JF; Matthews J; Wolf M; Stone J; Juneja S
    Eur J Haematol; 2006 Jun; 76(6):473-80. PubMed ID: 16529599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
    Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
    J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of concordant and discordant cytomorphology of bone marrow involvement in patients with diffuse, large, B-cell lymphoma treated with R-CHOP.
    Shim H; Oh JI; Park SH; Jang S; Park CJ; Huh J; Suh C; Chi HS
    J Clin Pathol; 2013 May; 66(5):420-5. PubMed ID: 23610041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement.
    Lee KW; Yi J; Choi IS; Kim JH; Bang SM; Kim DW; Im SA; Kim TY; Yoon SS; Lee JS; Bang YJ; Park S; Kim BK; Cho HI; Heo DS
    Ann Hematol; 2009 Sep; 88(9):829-38. PubMed ID: 19172274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-assessment in diffuse large cell lymphoma at first relapse. A study by the Italian Intergroup for Lymphomas.
    Guglielmi C; Martelli M; Federico M; Zinzani PL; Vitolo U; Bellesi G; Santini G; Tarella C; Zallio F; Pregno P; Di Renzo N; Resegotti L;
    Haematologica; 2001 Sep; 86(9):941-50. PubMed ID: 11532622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Park MJ; Park SH; Park PW; Seo YH; Kim KH; Seo JY; Jeong JH; Kim MJ; Ahn JY; Hong J
    J Clin Pathol; 2015 Sep; 68(9):733-8. PubMed ID: 25998512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
    Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
    Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome.
    Chigrinova E; Mian M; Scandurra M; Greiner TC; Chan WC; Vose JM; Inghirami G; Chiappella A; Baldini L; Ponzoni M; Ferreri AJ; Franceschetti S; Gaidano G; Tucci A; Facchetti F; Lazure T; Lambotte O; Montes-Moreno S; Piris MA; Nomdedeu JF; Uccella S; Rancoita PM; Kwee I; Zucca E; Bertoni F
    Hematol Oncol; 2011 Mar; 29(1):38-41. PubMed ID: 20635329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and prognostic evaluation of bone marrow infiltration (biopsy versus aspirate) in early chronic lymphocytic leukemia. A single center study.
    Molica S; Tucci L; Levato D; Docimo C
    Haematologica; 1997; 82(3):286-90. PubMed ID: 9234573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
    Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
    Oki Y; Yamamoto K; Kato H; Kuwatsuka Y; Taji H; Kagami Y; Morishima Y
    Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical outcomes of different regimens for non-Hodgkin's lymphoma with bone marrow involvement: analysis of 148 cases].
    Li QC; Yuan XL; Wang YF; Zou DH; Zhao YZ; Qiu LG
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):254-7. PubMed ID: 18361837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma.
    Porrata LF; Ristow K; Habermann TM; Witzig TE; Inwards DJ; Markovic SN
    Am J Hematol; 2009 Feb; 84(2):93-7. PubMed ID: 19123458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can flow cytometry of bone marrow aspirate predict outcome of patients with diffuse large B cell lymphoma? A retrospective single centre study.
    Wolach O; Fraser A; Luchiansky M; Shapiro C; Radnay J; Shpilberg O; Lishner M; Lahav M
    Hematol Oncol; 2015 Mar; 33(1):42-7. PubMed ID: 24470400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
    Natkunam Y; Farinha P; Hsi ED; Hans CP; Tibshirani R; Sehn LH; Connors JM; Gratzinger D; Rosado M; Zhao S; Pohlman B; Wongchaowart N; Bast M; Avigdor A; Schiby G; Nagler A; Byrne GE; Levy R; Gascoyne RD; Lossos IS
    J Clin Oncol; 2008 Jan; 26(3):447-54. PubMed ID: 18086797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does follicularity in large cell lymphoma predict outcome after autologous stem cell transplantation?
    Krishnan A; Nademanee A; Fung H; Angelopoulou M; Molina A; Gaal K; Dagis A; Palmer J; Alvarnas J; Slovak M; Kogut N; Popplewell L; Rodriguez R; Schriber J; Wang S; Forman SJ
    Biol Blood Marrow Transplant; 2006 Jun; 12(6):641-7. PubMed ID: 16737937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occult bone marrow involvement in patients with diffuse large B-cell lymphoma: results of a pilot study.
    Talaulikar D; Dahlstrom JE; Shadbolt B; McNiven M; Broomfield A; Pidcock M
    Pathology; 2007 Dec; 39(6):580-5. PubMed ID: 18027262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow biopsy in non-Hodgkin lymphoma: a morphological study.
    Kumar S; Rau AR; Naik R; Kini H; Mathai AM; Pai MR; Khadilkar UN
    Indian J Pathol Microbiol; 2009; 52(3):332-8. PubMed ID: 19679954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
    Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S
    Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognostic value of a focal bone marrow lesion in diffuse large B-cell lymphosarcoma].
    Magomedova AU; Kremenetskaia AM; Vorob'ev IA; Kravchenko SK; Kaplanskaia IB; Samoĭlova RS; Gemdzhian EG; Vorob'ev AI
    Ter Arkh; 2004; 76(7):60-3. PubMed ID: 15379130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.